Auranofin (AUR) is an orally available lipophilic gold-based anti-inflammatory compound
used for the treatment of rheumatoid arthritis (RA). Recent evidence indicates that AUR may …

Advanced stages of cancer are highly associated with short overall survival in patients due
to the lack of long-term treatment options following the standard form of care. New options …

Approximately 50%–55% of high-grade serous ovarian carcinoma (HGSOC) patients have
MYC oncogenic pathway activation. Because MYC is not directly targetable, we have …

Auranofin (AF) is a potent, off-patent thioredoxin reductase (TrxR) inhibitor that efficiently
targets cancer via reactive oxygen species (ROS)-and DNA damage-mediated cell death …

Simple Summary High-grade serous ovarian cancer (HGSOC) is the most prevalent type of
ovarian cancer, accounting for 70% of ovarian cancer deaths. This is primarily due to the …

Acute leukemia continues to be a major cause of death from disease worldwide and current
chemotherapeutic agents are associated with significant morbidity in survivors. While better …

Auranofin is a thioredoxin reductase-1 inhibitor originally approved for the treatment of
rheumatoid arthritis. Recently, auranofin has been repurposed as an anticancer drug, with …

Aims Studies in the past have shown that inhibition of the ataxia telangiectasia and Rad3-
related (ATR) kinase sensitizes cancer cells to genotoxic anticancer treatments, however …

Plant-derived bioactive products and their structural diversity have made a significant
contribution to various pharmacological activities including cancer and other infectious …

Glioblastoma (GBM) is the most aggressive primary brain tumor. Recently, agents increasing
the level of oxidative stress have been proposed as anticancer drugs. However, their …